Regeneron Drugs on Monday announced prepares to acquire hereditary screening business 23andMe for $256 million.
The New York-based drugmaker is readied to take control of 23andMe after winning an insolvency public auction for the troubling company, Regeneron stated.
Regeneron strategies to “proceed all customer genome solutions continuous,” the business kept in mind in a statement.
” Our company believe we can assist 23andMe provide and build on its goal to assist individuals discover their very own DNA and exactly how to boost their individual wellness, while enhancing Regeneron’s initiatives to boost the wellness and health of several,” Regeneron Head of state George Yancopoulos stated.
In March, 23andMe declared Phase 11 insolvency, saying it would certainly get in a “court-supervised” sale procedure. At the very same time, the business’s chief executive officer, Anne Wojcicki, surrendered from her duty as president.
The action complied with a collection of problems for the business, consisting of a 2023 class-action settlement over an information violation and a mass resignation amongst its board of supervisors in 2024.
Established In 2006, 23andMe assisted leader customer hereditary screening however dealt with trouble transforming the solution right into a lasting organization.
The insolvency evoked concerns concerning the protection of hereditary information coming from the business’s approximately 15 million consumers.
A sight of 23andMe head office in Sunnyvale, Calif., March 25, 2025.
Tayfun Coskun/Anadolu through Getty Photos
Regeneron on Monday swore to preserve the information personal privacy procedure used by 23andMe.
” Regeneron plans to make sure conformity with 23andMe’s customer personal privacy plans and appropriate legislations relative to the therapy of consumer information,” the business stated.
The procurement of 23andMe will certainly not consist of Lemonaid Wellness, a telemedicine solution that 23andMe acquired for around $400 million in 2021.
Regeneron indicated its very own hereditary screening of some 3 million individuals throughout numerous study studies, claiming the info had actually assisted promote pharmaceutical innovations.
” We share 23andMe’s starting vision of the power of genes and information and the wellness advantages to people and culture in recognizing the human genome,” Regeneron stated. “Our company believe we are distinctively matched to be liable and reliable guardians of 23andMe’s future, and we anticipate inviting their skilled group.”
ABC Information’ Mary Kekatos added to this record.
